Abbott Diagnostics

Abbott Diagnostics is the diagnostics business of Abbott Laboratories, a diversified United States healthcare company. It develops and supplies technologies used to identify disease, monitor health conditions, support clinical decisions, and screen donated blood. Its portfolio spans laboratory instruments, assay reagents, software, consumables, and near-patient testing platforms used by hospitals, independent laboratories, physician offices, emergency departments, pharmacies, blood banks, and other healthcare providers. The business covers several major diagnostic disciplines. Core laboratory systems support high-volume clinical chemistry and immunoassay testing, while hematology and transfusion-related products are used to evaluate blood components and support blood-bank operations. Abbott also offers molecular and infectious-disease testing, including rapid and point-of-care platforms designed to produce results closer to the patient. Cardiac, toxicology, diabetes-related, and other specialized testing areas complement the central laboratory portfolio. Among the best-known Abbott Diagnostics platform families are Alinity, a connected suite of laboratory systems; ARCHITECT, a widely used family of immunoassay and clinical chemistry analyzers; ID NOW, a rapid molecular testing platform; and Afinion, a point-of-care analyzer used for selected chronic-disease and cardiovascular-risk tests. The exact products available, regulatory clearances, and intended uses vary by country and by clinical setting. Abbott Diagnostics is positioned around improving access to timely and actionable diagnostic information. Its business model combines capital equipment with recurring revenue from reagents, cartridges, consumables, service, and software. Abbott’s diagnostics activities also include screening technologies used by blood centers to test donations for infectious agents, an area with public-health importance beyond routine patient testing. The brand operates as part of Abbott rather than as an independently listed company. Abbott Laboratories reports diagnostics as one of its principal business areas alongside medical devices, nutrition, and established pharmaceutical products. Abbott Diagnostics therefore shares corporate infrastructure, research capabilities, regulatory operations, and commercial reach with the wider Abbott organization. Publicly available reference material supplied for this entry does not establish a separate founding date, independent headquarters, or a complete historical chronology for the diagnostics brand itself.

Abbott Diagnostics is best understood as a business division and commercial brand within Abbott Laboratories, not as a separately incorporated public company with its own independently documented founding history. Abbott’s broader healthcare activities have included diagnostic testing for many decades, but the supplied reference material does not provide a reliable date for the creation of the Abbott Diagnostics brand or a complete account of the acquisitions and reorganizations that shaped its present portfolio. The business has developed across several layers of laboratory medicine. Traditional laboratory diagnostics form its foundation, including clinical chemistry, immunoassay, hematology, and related systems that allow hospitals and independent laboratories to process large volumes of specimens. These activities rely on an installed base of analyzers and recurring purchases of assay reagents, calibrators, controls, and consumables. Abbott has also built capabilities in blood screening, where diagnostic systems are used to assess donated blood for relevant infectious risks. A second major direction has been the movement of testing closer to the patient. Point-of-care and rapid-testing platforms are designed to reduce the time between specimen collection and clinical decision-making. Abbott’s ID NOW and Afinion families represent this emphasis, while its molecular and other specialized technologies address infectious disease, cardiac care, chronic disease, and additional clinical applications. Alinity represents Abbott’s effort to provide a coordinated family of laboratory instruments and related solutions across multiple testing disciplines. The diagnostics business has also been affected by changing public-health needs and by the growing importance of decentralized testing. Rapid diagnostic capacity became especially prominent during the COVID-19 pandemic, when Abbott’s molecular and antigen-testing products received attention in multiple markets. However, the specific regulatory milestones, sales figures, product launches, and organizational changes associated with that period are not documented in the supplied materials and are therefore not listed here as independently verified events. Today, Abbott Diagnostics operates through Abbott Laboratories’ international commercial, manufacturing, research, and regulatory network. Its scope extends from high-throughput laboratory automation to near-patient testing and blood-screening applications. The division’s continuing strategic challenge is to balance analytical performance, speed, ease of use, connectivity, affordability, and regulatory compliance across very different healthcare environments. Because no reliable standalone Wikipedia article or detailed historical source was supplied for this exact brand subject, this entry treats Abbott Diagnostics as Abbott’s diagnostics business and avoids attributing a separate corporate history to it.

A broad, globally distributed diagnostics platform serving central laboratories, point-of-care settings, blood banks, and other healthcare providers, with emphasis on integrated systems, rapid testing, and clinically actionable results.

• AlinityIntegrated laboratory diagnostics

  Alinity is Abbott’s family of laboratory diagnostic systems and related products. It is intended to support multiple areas of routine laboratory testing through standardized instruments, assays, consumables, and connectivity. Depending on the market and configuration, the Alinity portfolio can address disciplines such as clinical chemistry, immunoassay, hematology, and other laboratory workflows. Its role is to help laboratories increase automation, manage testing capacity, and connect analytical results with broader laboratory information systems.

• ARCHITECTClinical chemistry and immunoassay systems

  ARCHITECT is a family of Abbott laboratory analyzers and assays used primarily in clinical chemistry and immunoassay testing. The systems are designed for professional laboratories processing routine and specialized patient samples. Their associated reagent and consumable ecosystem supports recurring testing across areas such as infectious disease, endocrinology, cardiac assessment, and general chemistry, subject to the clearances and intended uses applicable in each market.

• ID NOWRapid molecular diagnostics

  ID NOW is Abbott’s rapid molecular testing platform for near-patient use. It is designed to provide molecular test results in settings where waiting for centralized laboratory processing may delay treatment or operational decisions. The platform has been associated with testing for respiratory and other infectious diseases, although the available tests, claims, and regulatory status depend on jurisdiction. It is used in healthcare and other authorized testing environments rather than as a general-purpose consumer product.

• AfinionPoint-of-care testing

  Afinion is Abbott’s point-of-care testing platform for selected tests used in physician offices, clinics, and other near-patient settings. The system is associated with measurements relevant to diabetes management and cardiovascular-risk assessment, including tests that can support rapid clinical evaluation. Its value proposition is to combine a compact analyzer with dedicated test cartridges or consumables so that results can be generated during a patient visit, subject to local authorization.

1. Abbott: Life-Changing Healthcare Technologies
2. Abbott corporate website